256 related articles for article (PubMed ID: 31436251)
1. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
2. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
3. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
4. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
5. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
7. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
8. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
Liang X; Li Q; Xu B; Hu S; Wang Q; Li Y; Zong Y; Zhang S; Li C
Int J Clin Oncol; 2019 Sep; 24(9):1061-1068. PubMed ID: 31065835
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
12. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
13. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Shi M; Ma J; Feng M; Liang L; Chen H; Wang T; Xie Z
Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998
[TBL] [Abstract][Full Text] [Related]
14. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
15. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
16. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
Heist RS; Shim HS; Gingipally S; Mino-Kenudson M; Le L; Gainor JF; Zheng Z; Aryee M; Xia J; Jia P; Jin H; Zhao Z; Pao W; Engelman JA; Iafrate AJ
Oncologist; 2016 Apr; 21(4):481-6. PubMed ID: 27022036
[TBL] [Abstract][Full Text] [Related]
17. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Vuong HG; Ho ATN; Altibi AMA; Nakazawa T; Katoh R; Kondo T
Lung Cancer; 2018 Sep; 123():76-82. PubMed ID: 30089599
[TBL] [Abstract][Full Text] [Related]
19. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
20. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
